EMA grants marketing authorization to Alkindi for treatment of primary adrenal insufficiency

724 Views

eMediNexus 19 December 2017

The European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a paediatric-use marketing authorisation for Alkindi (hydrocortisone) for the treatment of primary adrenal insufficiency, a rare hormonal disorder, in infants, children and adolescents.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.